KRAS and neoplasm: Accordingly, Canon et al. recently demonstrated that treatment of KRAS G12C mutant tumors with a G12C-specific inhibitor induced a pronounced tumor regression and long-lasting responses when used alone or in combination with immunotherapy, by promoting a proinflammatory TME.